Sandu Pharma Q1 FY27 Results: Revenue Rs 16 Cr, PAT Rs 0.23 Cr and Key Highlights

August 12, 2026
Posted by: Kunal Singla
Category: News

Sandu Pharma Q1 FY27: Revenue Rs 16 Cr (-1.86% YoY). PAT Rs 0.23 Cr (+2.19% YoY). Results August 11, 2026. CMP Rs 39.48.

Sandu Pharma Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 0.23 crore, up 2.19% from Rs 0.22 crore in Q1 FY26. Revenue from operations contracted 1.86% year on year to Rs 16 crore from Rs 16 crore in Q1 FY26. The Sandu Pharma Q1 FY27 results are on a standalone basis for the quarter ended June 30, 2026.

Click Here – Get Free Investment Predictions

Table of Contents

Sandu Pharma Q1 FY27 Financial Highlights

The table below presents key financial metrics from the Sandu Pharma Q1 FY27 results compared with Q1 FY26.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue from Operations (Rs Cr)	Rs 16 Cr	Rs 16 Cr	-1.86%
Gross Profit (Rs Cr)	Rs 0.37 Cr	Rs 0.35 Cr	+7.37%
Net Profit / (Loss) – PAT (Rs Cr)	Rs 0.23 Cr	Rs 0.22 Cr	+2.19%

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends and growth potential for 2026.

Discover stocks investors are actively accumulating
High-conviction opportunities backed by research
Designed for the next phase of market growth

Unlock the latest Top Stock Picks on Univest

See the Stocks →

Sandu Pharma Q1 FY27 Performance Analysis

Use the Univest Screener to Track Live Fundamentals of Indian Stocks

The Sandu Pharma Q1 FY27 results show a revenue decline of 1.86% year on year to Rs 16 crore. Gross profit stood at Rs 0.37 crore against Rs 0.35 crore in Q1 FY26.

Net profit in the June 2026 quarter stood at Rs 0.23 crore, a 2.19% rise year on year. Investors should verify these figures against official BSE and NSE filings.

Key Business Factors in Sandu Pharma Q1 FY27

1. Revenue Trend in the June 2026 Quarter

Revenue contracted 1.86% year on year to Rs 16 crore, reflecting near-term headwinds in the Pharmaceuticals segment.

2. Gross Profit and Margin Movement

Gross profit rose to Rs 0.37 crore from Rs 0.35 crore in Q1 FY26. Improved cost efficiency contributed.

3. Net Profit Outcome in Q1 FY27

PAT came in at Rs 0.23 crore, up 2.19% from Rs 0.22 crore in Q1 FY26. Sustained profitability will depend on revenue and margin trends through FY27.

Dividend Details

No dividend has been declared alongside the Sandu Pharma Q1 FY27 results for the quarter ended June 2026. Investors may track any future announcements on BSE and NSE.

Sandu Pharma FY27 Outlook After Q1 Results

The June 2026 quarterly results for Sandu Pharma present a mixed picture heading into FY27. Gross margin improvement will be critical to strengthening the financial position. Investors should monitor management guidance, Pharmaceuticals sector conditions, and any strategic developments through the year.

Sandu Pharma Stock Performance

Download the Univest iOS App or Univest Android App to track Sandu Pharma live share price and upcoming quarterly results.

Sandu Pharma share price stood at Rs 39.48 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals company’s financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before any investment decision.

Key Risks to Watch After Sandu Pharma Q1 FY27 Results

1. Sector-Specific Demand Headwinds

A slowdown in the Pharmaceuticals sector could weigh on Sandu Pharma revenue and profitability beyond what the June 2026 quarter currently indicates.

2. Input Cost and Margin Pressure

Rising raw material or operational costs could compress gross margins and limit net profit improvement in subsequent quarters of FY27.

3. Macroeconomic and Regulatory Uncertainty

Inflation, interest rate movements, and regulatory shifts remain key risks to the Sandu Pharma earnings trajectory through FY27.

Conclusion

Sandu Pharma Q1 FY27 results report revenue of Rs 16 crore and a net profit (PAT) of Rs 0.23 crore, up 2.19% from Rs 0.22 crore in Q1 FY26. The June 2026 quarterly performance reflects the company’s position in the Pharmaceuticals space. Investors should study the complete financials on BSE and NSE and consult a SEBI-registered advisor before any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Sandu Pharma Q1 FY27 Results

When were the Sandu Pharma Q1 FY27 results announced?

Ans. The June 2026 quarterly results for Sandu Pharma were announced on August 11, 2026, covering the quarter ended June 30, 2026. The standalone results were filed with BSE and NSE on the same date.

What is the PAT in the Sandu Pharma Q1 FY27 results?

Ans. PAT (net profit) stood at Rs 0.23 crore in the June 2026 quarter, up 2.19% from Rs 0.22 crore in Q1 FY26.

What was the revenue in the Sandu Pharma Q1 FY27 results?

Ans. Revenue for the June 2026 quarter fell 1.86% year on year to Rs 16 crore from Rs 16 crore in Q1 FY26.

Did Sandu Pharma announce any dividend with the Q1 FY27 results?

Ans. No dividend has been declared alongside the June 2026 quarterly results of Sandu Pharma. Investors may track future dividend announcements on BSE and NSE portals.

What is the Sandu Pharma FY27 outlook after Q1 results?

Ans. The June 2026 quarterly data signals a challenging start to FY27 for Sandu Pharma. Revenue trends, margin performance, and Pharmaceuticals sector demand will be the key factors to watch.

Is Sandu Pharma a good buy after Q1 FY27 results?

Ans. The Q1 FY27 performance of Sandu Pharma reflects improving trends. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.